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Abstract
Mass drug administration (MDA) of antimalarials has re-emerged as a recommended tool for interrupting malaria
transmission, but evidence from low endemicity settings is scarce. A trial in Zanzibar found that two rounds of MDA
made no significant impact on malaria incidence, and many questions on the optimal mode and setting for
implementing MDA remain unanswered. A more thorough understanding of local sources and drivers of
transmission, and a better toolbox for evaluating interventions in near-elimination settings are essential.
Please see related research article: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-018-1202-8.
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Background
As the World Health Organization reports stagnation
in the fight against malaria [1], urgent efforts are
needed to avoid the reversal of recent gains. In some
places, this may mean increasing the coverage of vector
control, such as long-lasting insecticidal nets (LLIN)
and indoor residual spraying, or improving access to ef-
ficacious treatments, including for cases of Plasmodium
vivax or artemisinin-resistant P. falciparum. Other
places may have exhausted the available repertoire of
standard tools, and complementary interventions are
required to tackle ongoing transmission. In pre-
elimination settings, low level transmission appears to
be particularly difficult to tackle because interventions
must be increasingly targeted, requiring a more thor-
ough understanding of local patterns of transmission
and a robust and adaptable health system [2].
Mass drug administration (MDA), the time-limited
administration of antimalarial treatment to everyone at
about the same time and at repeated intervals [1], has
re-emerged as a recommended tool to accelerate the
interruption of transmission in areas approaching
elimination [3]. Easily applicable diagnostic tools are
simply not yet sensitive enough to detect the last para-
site; hence they leave large parts of the asymptomatic
reservoir undetected [4]. Interestingly, the recommen-
dation for MDA is based on weak evidence, particularly
with regard to demonstrating impact in low endemic
African settings [5], though modelling studies provide
some theoretical guidance [6].
In a trial conducted in Zanzibar by Morris and colleagues
[7], two rounds of MDA with dihydroartemisinin-
piperaquine (DHAP) were used, plus a single low dose of
primaquine (SLD PQ). The well-designed cluster-
randomised trial found no impact on malaria incidence and
only a marginal and transient effect on the prevalence of
asymptomatic infections, as determined by polymerase
chain reaction (PCR). These results are sobering, especially
given that the setting appeared operationally conducive and
a reasonable coverage level with DHAP was achieved, for
which modelling suggested a notable impact [6]. Further-
more, while coverage with SLD PQ could have been higher,
it is uncertain whether much better operational coverage
could be achieved under routine programme conditions.
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The authors attribute the lack of impact to subopti-
mal timing (during rather than before the peak mal-
aria season), a possibly insufficient number of MDA
rounds, and the importance of importation of infec-
tions. In the context of the latter, it is misleading to
refer to their outcome as “transmission” because this
is not what was assessed. Measuring transmission in
near-elimination settings remains a unique challenge;
therefore – as in the study by Morris et al. – proxy
measures are applied [8]. However, in Zanzibar and
similar settings, the relative contributions of local
transmission and imported infections remain an im-
portant factor of uncertainty, despite several previous
investigations, and the reliability of routinely reported
travel history is unclear [9].
The measurement of adherence using blood concen-
tration of piperaquine in intervention areas (as was
done in the study by Morris et al.) is welcome because
it is known that self-reporting of medication intake is
unreliable [10, 11]. However, it would have been useful
to measure the blood concentration of a variety of anti-
malarials in both intervention and control areas. Wide-
spread unreported use of antimalarials (obtained from
health facilities and private retailers) has been docu-
mented in Tanzania [11] and might have modified the
effect of MDA rounds.
The results from this study are nevertheless highly
relevant. Firstly, they underline the importance and
value of real-world data generated by well designed
epidemiological and intervention studies to validate
the prediction of models. Secondly, as transmission
declines and heterogeneity increases, a thorough un-
derstanding of the target of malaria control efforts is
required. This is particularly true in environments
with a high transmission potential. In the study by
Morris et al., prevalence by PCR differed considerably
between intervention and control areas. It increased
in intervention areas (from 0.8% to 1.7%) and de-
creased in control areas (from 2.5% to 1.4%), suggest-
ing that the study did not capture important drivers
of the local epidemiology. Thirdly, indicators for
measuring the effect of interventions in low transmis-
sion settings must be carefully chosen. Small changes
are difficult to detect, minor contextual fluctuations
(and major ones, such as the redistribution of LLIN)
may mask intervention effects, and sufficient detail is
required to explain unexpected study outcomes. In
such a context, it is particularly important – albeit
difficult – to identify the source of local infections be-
cause not all may represent local transmission.
Conclusions
Many questions about the optimal mode and setting
for implementing MDA remain unanswered. However,
trials, such as the one by Morris et al., make a use-
ful contribution to the evidence base on how to ad-
dress ongoing transmission in near-elimination
settings. Ideally, they would be complemented by
more in-depth investigations of the drivers of local
malaria epidemiology.
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